Matching articles for "Rifampin"
Issue 1644 · February 21, 2022
Odevixibat (Bylvay) for Progressive Familial Intrahepatic Cholestasis-Associated Pruritus

Odevixibat ( Bylvay – Albireo), an oral ileal bile acid transporter (IBAT) inhibitor, has been approved by the FDA for treatment of pruritus in patients ≥3 months old with progressive familial intrahepatic…

Med Lett Drugs Ther. 2022 Feb 21; 64(1644):28
Odevixibat ( Bylvay – Albireo), an oral ileal bile acid transporter (IBAT) inhibitor, has been approved by the FDA for treatment of pruritus in patients ≥3 months old with progressive familial intrahepatic cholestasis (PFIC). It is the first drug to be approved in the US for this indication.
Issue 1644 · February 21, 2022
Cabotegravir (Apretude) for HIV-1 Pre-Exposure Prophylaxis

The FDA has approved Apretude (ViiV Healthcare), an IM extended-release (ER) formulation of the integrase strand transfer inhibitor (INSTI) cabotegravir, for use every 2 months to prevent sexually acquired…

Med Lett Drugs Ther. 2022 Feb 21; 64(1644):29-31
The FDA has approved Apretude (ViiV Healthcare), an IM extended-release (ER) formulation of the integrase strand transfer inhibitor (INSTI) cabotegravir, for use every 2 months to prevent sexually acquired HIV-1 infection in at-risk adolescents and adults. Apretude is the first ER formulation to be FDA-approved for pre-exposure prophylaxis (PrEP) of HIV-1 infection.
Issue 1631 · August 23, 2021 Free
In Brief: A Shorter Treatment Regimen for Tuberculosis (online only)

In a clinical trial conducted by the CDC's Tuberculosis Trials Consortium in collaboration with the NIH-funded AIDS Clinical Trials Group, a new 4-month regimen for treatment of drug-susceptible pulmonary…

Med Lett Drugs Ther. 2021 Aug 23; 63(1631):e3
In a clinical trial conducted by the CDC's Tuberculosis Trials Consortium in collaboration with the NIH-funded AIDS Clinical Trials Group, a new 4-month regimen for treatment of drug-susceptible pulmonary tuberculosis was found to be noninferior to 6 months of standard treatment.
Issue 1629 · July 26, 2021 Free
In Brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 Vaccines (online only)

On June 25, 2021, the FDA added a warning to the Fact Sheets for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) about an increased risk of myocarditis and…

Med Lett Drugs Ther. 2021 Jul 26; 63(1629):e9
On June 25, 2021, the FDA added a warning to the Fact Sheets for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) about an increased risk of myocarditis and pericarditis following administration of the vaccines.
Issue 1531 · October 9, 2017
Mavyret and Vosevi - Two New Combinations for Chronic HCV Infection

The FDA has approved Mavyret (Abbvie) and Vosevi (Gilead), two new fixed-dose combinations of direct-acting antiviral (DAA) drugs, for treatment of chronic hepatitis C virus (HCV) infection caused by any of…

Med Lett Drugs Ther. 2017 Oct 9; 59(1531):166-70
The FDA has approved Mavyret (Abbvie) and Vosevi (Gilead), two new fixed-dose combinations of direct-acting antiviral (DAA) drugs, for treatment of chronic hepatitis C virus (HCV) infection caused by any of the six major HCV genotypes in patients without cirrhosis or with compensated cirrhosis. Both are approved for use in treatment-experienced patients. Mavyret is also approved for treatment-naive patients.
Issue 1526 · July 31, 2017
Drugs for Epilepsy

Treatment of epilepsy should begin with a single antiepileptic drug (AED), increasing its dosage gradually until seizures are controlled or adverse effects become intolerable. If seizures persist, specialists…

Med Lett Drugs Ther. 2017 Jul 31; 59(1526):121-30
Treatment of epilepsy should begin with a single antiepileptic drug (AED), increasing its dosage gradually until seizures are controlled or adverse effects become intolerable. If seizures persist, specialists generally recommend trying at least one and sometimes a second alternative drug as monotherapy before considering use of two drugs concurrently. When used for the appropriate seizure type, AEDs are roughly equivalent in efficacy. Drug choice is usually based on factors such as ease of use, adverse effects, drug interactions, presence of comorbidities, and cost.
Issue 1480 · October 26, 2015
Drugs for Hypothyroidism

Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy, or radioactive iodine therapy. Treatment of hypothyroidism with replacement doses of thyroid hormone is usually lifelong.…

Med Lett Drugs Ther. 2015 Oct 26; 57(1480):147-50
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy, or radioactive iodine therapy. Treatment of hypothyroidism with replacement doses of thyroid hormone is usually lifelong. Levothyroxine is the drug of choice.
Issue 1465 · March 30, 2015
Edoxaban (Savaysa) - The Fourth New Oral Anticoagulant

The FDA has approved edoxaban ( Savaysa – Daiichi Sankyo), a once-daily, oral, direct factor Xa inhibitor, for treatment of venous thromoboembolism (VTE) and for prevention of stroke and systemic embolism in…

Med Lett Drugs Ther. 2015 Mar 30; 57(1465):43-5
The FDA has approved edoxaban ( Savaysa – Daiichi Sankyo), a once-daily, oral, direct factor Xa inhibitor, for treatment of venous thromoboembolism (VTE) and for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is the fourth new oral anticoagulant to be approved for VTE and nonvalvular atrial fibrillation.
Issue 1449 · August 18, 2014
Two New Drugs for Skin and Skin Structure Infections

The FDA has approved two new drugs for treatment of adults with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. Dalbavancin ( Dalvance – Durata) is a…

Med Lett Drugs Ther. 2014 Aug 18; 56(1449):73-5
The FDA has approved two new drugs for treatment of adults with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. Dalbavancin ( Dalvance – Durata) is a long-acting intravenous (IV) lipoglycopeptide antibiotic similar to telavancin (Vibativ) . Tedizolid phosphate ( Sivextro – Cubist) is an IV and oral oxazolidinone antibacterial drug similar to linezolid (Zyvox) . A third IV antibiotic, oritavancin (Orbactiv) , recently approved by the FDA for the same indication, will be reviewed in a future issue.
Issue 1446 · July 7, 2014
Treatment of Atrial Fibrillation

The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been published.

Med Lett Drugs Ther. 2014 Jul 7; 56(1446):53-8
The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been published.
Issue 1431 · December 9, 2013 Free
In Brief: Prevention of Meningococcal B Disease

An outbreak (8 cases to date) of meningococcal disease at Princeton University caused by Neisseria meningitidis serogroup B has led the FDA and CDC to permit importation and investigational use (at Princeton…

Med Lett Drugs Ther. 2013 Dec 9; 55(1431):97
An outbreak (8 cases to date) of meningococcal disease at Princeton University caused by Neisseria meningitidis serogroup B has led the FDA and CDC to permit importation and investigational use (at Princeton University only) of a meningococcus B vaccine (4CMenB; Bexsero – Novartis) that has not been approved in the US. Bexsero has been approved for use in the European Union and in Australia. THE VACCINE — Until recently, no serogroup B vaccine was widely available because the polysaccharide capsule of the B serogroup, unlike those of the other main meningococcal serogroups (A, C, Y, and W-135), is only weakly immunogenic. The 4CMenB vaccine contains 3 protein antigens identified in the N. meningitidis serogroup B genome and membrane components from a New Zealand outbreak strain. The vaccine has been tested in more than 8000 adults and children, has proved to be immunogenic, and appears to be safe. 1 Its efficacy has not been established clinically, but laboratory testing, according to the CDC, has found that the vaccine should be protective against the strain causing the Princeton University outbreak. Bactericidal antibody levels develop about 2 weeks after one dose of the vaccine; a second dose is needed 1-6 months after the first to maintain protection. CHEMOPROPHYLAXIS — Close contacts of patients with invasive meningococcal disease (e.g., same household, roommates, boyfriend or girlfriend) should receive antimicrobial chemoprophylaxis. Antimicrobial drugs can prevent secondary cases and eradicate the organism from the nasopharynx of healthy carriers. The susceptibility of serogroup B meningococci to antimicrobial agents is the same as that of other meningococcal serogroups. Regimens recommended by the CDC’s Advisory Committee on Immunization Practices are: oral rifampin 600 mg (10 mg/kg for children) q12h for 2 days; oral ciprofloxacin 500 mg once (not recommended for children); or a single IM injection of ceftriaxone 250 mg (125 mg for children). 2 CONCLUSION — The new vaccine against serogroup B meningococcal disease, which is investigational in the US, appears to be immunogenic and safe. For immediate protection after close contact with an infected patient, antimicrobial prophylaxis is recommended. 1. NJ Carter. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero®): a review of its use in primary and booster vaccination. BioDrugs 2013; 27:263. 2. AC Cohn et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62(RR-2):1. Download complete U.S. English article
Issue 1423 · August 19, 2013
Bedaquiline (Sirturo) for Multidrug-Resistant Tuberculosis

Bedaquiline (bed ak' wi leen; Sirturo – Janssen), a diarylquinoline antimycobacterial, has been given accelerated approval by the FDA as an orphan drug for use in addition to other drugs for treatment of…

Med Lett Drugs Ther. 2013 Aug 19; 55(1423):66-8
Bedaquiline (bed ak' wi leen; Sirturo – Janssen), a diarylquinoline antimycobacterial, has been given accelerated approval by the FDA as an orphan drug for use in addition to other drugs for treatment of adults with multidrug-resistant pulmonary tuberculosis (MDR-TB). It is the first drug approved specifically to treat MDR-TB.
Issue 116 · April 1, 2012
Drugs for Tuberculosis

Tuberculosis (TB) is still a common cause of death worldwide, and the prevalence of drug-resistant TB poses challenges to its treatment and control. Guidelines with detailed management recommendations are…

Treat Guidel Med Lett. 2012 Apr; 10(116):29-36
Tuberculosis (TB) is still a common cause of death worldwide, and the prevalence of drug-resistant TB poses challenges to its treatment and control. Guidelines with detailed management recommendations are available from the American Thoracic Society, Centers for Disease Control and Prevention (CDC) and Infectious Diseases Society of America (IDSA).
Issue 88 · December 1, 2009
Antifungal Drugs

The drugs of choice for treatment of some fungal infections are listed. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines are available online…

Treat Guidel Med Lett. 2009 Dec; 7(88):95-102
The drugs of choice for treatment of some fungal infections are listed. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines are available online from the Infectious Diseases Society of America ( www.idsociety.org ).
Issue 1326 · November 30, 2009
Tolvaptan (Samsca) for Hyponatremia

The FDA has approved the marketing of tolvaptan ( Samsca - Otsuka), an oral vasopressin receptor antagonist, for treatment of hypervolemic or euvolemic hyponatremia due to congestive heart failure (CHF),…

Med Lett Drugs Ther. 2009 Nov 30; 51(1326):95-6
The FDA has approved the marketing of tolvaptan ( Samsca - Otsuka), an oral vasopressin receptor antagonist, for treatment of hypervolemic or euvolemic hyponatremia due to congestive heart failure (CHF), cirrhosis or the syndrome of inappropriate antidiuretic hormone secretion (SIADH). A similar drug, conivaptan ( Vaprisol ) is already available for intravenous (IV) treatment of euvolemic hyponatremia in hospitalized patients. Tolvaptan was approved by the FDA for both inpatient and outpatient use, but it should be started in a hospital.
Issue 1324 · November 2, 2009
Saxagliptin (Onglyza) for Type 2 Diabetes

Saxagliptin ( Onglyza - Bristol-Myers Squibb), the second oral dipeptidyl peptidase-4 (DPP-4) inhibitor to be marketed in the US, has been approved by the FDA for treatment of adults with type 2 diabetes.

Med Lett Drugs Ther. 2009 Nov 2; 51(1324):85-6
Saxagliptin ( Onglyza - Bristol-Myers Squibb), the second oral dipeptidyl peptidase-4 (DPP-4) inhibitor to be marketed in the US, has been approved by the FDA for treatment of adults with type 2 diabetes.
Issue 1322 · October 5, 2009
Dronedarone (Multaq) for Atrial Fibrillation

Dronedarone ( Multaq - Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter. Amiodarone (Cordarone, and others) is the most effective drug for this indication, but…

Med Lett Drugs Ther. 2009 Oct 5; 51(1322):78-80
Dronedarone ( Multaq - Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter. Amiodarone (Cordarone, and others) is the most effective drug for this indication, but has considerable toxicity.
Issue 86 · October 1, 2009
Drugs for Tuberculosis

Even though the incidence continues to decline in the United States, tuberculosis (TB) is still a common cause of death worldwide, and the prevalence of drug-resistant TB poses severe challenges to its…

Treat Guidel Med Lett. 2009 Oct; 7(86):75-82
Even though the incidence continues to decline in the United States, tuberculosis (TB) is still a common cause of death worldwide, and the prevalence of drug-resistant TB poses severe challenges to its treatment and control. Guidelines with detailed management recommendations are available from the Centers for Disease Control and Prevention (CDC), American Thoracic Society and Infectious Diseases Society of America (IDSA).
Issue 84 · August 1, 2009
Drugs for Thyroid Disorders

Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.

Treat Guidel Med Lett. 2009 Aug; 7(84):57-64
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Issue 1311 · May 4, 2009
Fesoterodine (Toviaz) for Overactive Bladder

The FDA has approved the marketing of fesoterodine ( Toviaz - Pfizer), a muscarinic receptor antagonist, for treatment of overactive bladder. It is the sixth antimuscarinic drug approved for this indication.

Med Lett Drugs Ther. 2009 May 4; 51(1311):34-5
The FDA has approved the marketing of fesoterodine ( Toviaz - Pfizer), a muscarinic receptor antagonist, for treatment of overactive bladder. It is the sixth antimuscarinic drug approved for this indication.
Issue 79 · March 1, 2009
Drugs for Insomnia

The majority of patients with insomnia do not have a predisposing psychiatric disease. Rather, untreated insomnia may be a risk factor for development of psychiatric problems such as depression or anxiety.

Treat Guidel Med Lett. 2009 Mar; 7(79):23-6
The majority of patients with insomnia do not have a predisposing psychiatric disease. Rather, untreated insomnia may be a risk factor for development of psychiatric problems such as depression or anxiety.
Issue 1297 · October 20, 2008
Drug Interactions with Simvastatin

A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin ( Zocor , and others) and green tea. Since it became…

Med Lett Drugs Ther. 2008 Oct 20; 50(1297):83-4
A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin ( Zocor , and others) and green tea. Since it became available generically, simvastatin has surpassed atorvastatin ( Lipitor ) as the best selling statin. As such, it is probably the most common cause of statin-induced myopathy, which is often a result of drug interactions.
Issue 73 · September 1, 2008
Drugs for Tobacco Dependence

Peptic ulcers caused by treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are mainly gastric ulcers. The greater the number of office visits and the longer the counseling time, the higher the…

Treat Guidel Med Lett. 2008 Sep; 6(73):61-5
Peptic ulcers caused by treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are mainly gastric ulcers. The greater the number of office visits and the longer the counseling time, the higher the smoking cessation rates have been.
Issue 1291 · July 28, 2008
Drugs for Travelers' Diarrhea

The most common cause of travelers' diarrhea, usually a self-limited illness without fever lasting several days, is infection with noninvasive enterotoxigenic (ETEC) or enteroaggregative (EAEC) strains of…

Med Lett Drugs Ther. 2008 Jul 28; 50(1291):58-9
The most common cause of travelers' diarrhea, usually a self-limited illness without fever lasting several days, is infection with noninvasive enterotoxigenic (ETEC) or enteroaggregative (EAEC) strains of Escherichia coli. Campylobacter, Shigella, Salmonella, Aeromonas, viruses and parasites are less common.
Issue 1288 · June 16, 2008 Free
Addendum: Warfarin-Acetaminophen Interaction

A reader expressed disappointment that our recent listing of “Some Warfarin Drug Interactions” 1 did not include acetaminophen. Perhaps it should have. Acetaminophen can increase the anticoagulant effect…

Med Lett Drugs Ther. 2008 Jun 16; 50(1288):45
A reader expressed disappointment that our recent listing of “Some Warfarin Drug Interactions” 1 did not include acetaminophen. Perhaps it should have. Acetaminophen can increase the anticoagulant effect of warfarin, particularly with continued use, but it does so inconsistently. The mechanism of this interaction has not been established, but may be related to an acetaminophen metabolite inhibiting vitamin K-epoxide reductase, the target for warfarin’s anticoagulant effect. 2 Patient susceptibility varies, possibly on a genetic basis; occasional use of acetaminophen generally has little or no effect on the international normalized ratio (INR) in patients on chronic warfarin therapy, but in some, even a few grams of the drug may cause a dramatic increase in INR. One study in healthy subjects found no effect of acetaminophen 4 g per day for 2 weeks, while another study in patients with the same acetaminophen dose for the same period of time found a moderate increase in INR. 3,4 It might be prudent to monitor INR in patients on chronic warfarin therapy more closely than usual when they take more than 2 g per day of acetaminophen for more than a few days. 1. Pharmacogenetic-based dosing of warfarin. Med Lett Drugs Ther 2008; 50:39. 2. HH Thijssen et al. Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. Thromb Haemost 2004; 92:797. 3. D Kwan et al. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999; 39:68. 4. I Mahe et al. Paracetamol: A haemorrhagic risk factor in patients on warfarin. Br J Clin Pharmacol 2005; 59:371. Download U.S. English
Issue 1286 · May 19, 2008
Pharmacogenetic-Based Dosing of Warfarin

Warfarin sodium ( Coumadin , and others) and other coumarin anticoagulants prevent thrombosis, but patient response is highly variable and overanticoagulation can lead to hemorrhage. Genotyping patients for…

Med Lett Drugs Ther. 2008 May 19; 50(1286):39-40
Warfarin sodium ( Coumadin , and others) and other coumarin anticoagulants prevent thrombosis, but patient response is highly variable and overanticoagulation can lead to hemorrhage. Genotyping patients for single nucleotide polymorphisms (SNPs) that affect coumarin metabolism and sensitivity may help clinicians estimate the therapeutic warfarin dose. The FDA has added a note to warfarin labeling recommending lowrange doses for patients with such genetic variations. Commercial tests for these variants are now available and cost about $500 per test.
Issue 1283 · April 7, 2008 Free
In Brief: Meningococcal Prophylaxis

The CDC recently reported that fluoroquinoloneresistant strains of Neisseria meningitidis have been detected for the first time in the US in an area around the border of North Dakota and Minnesota (CDC. MMWR,…

Med Lett Drugs Ther. 2008 Apr 7; 50(1283):25
The CDC recently reported that fluoroquinoloneresistant strains of Neisseria meningitidis have been detected for the first time in the US in an area around the border of North Dakota and Minnesota (CDC. MMWR, Feb 22, 2008). These isolates were all serogroup B, for which meningococcal vaccines ( Med Lett Drugs Ther 2005; 47:29 ) do not offer protection. Since many laboratories do not test N. meningitidis for antimicrobial susceptibility, it is possible that such resistance is more widespread. A single oral dose of ciprofloxacin ( Cipro , and others) 500 mg has been used for prophylaxis after close contact with infected patients. Oral rifampin ( Rifadin , and others) 600 mg (10 mg/kg for children) q12h for 2 days, a single IM injection of ceftriaxone ( Rocephin , and others) 250 mg (125 mg for children), or a single oral dose of azithromycin ( Zithromax , and others) 500 mg (10 mg/kg for children) are reasonable alternatives. Download U.S. English
Issue 65 · January 1, 2008
Antifungal Drugs

The drugs of choice for treatment of some fungal infections are listed in the tables. Some of the indications and dosages recommended here have not been approved by the FDA. Other guidelines are available from…

Treat Guidel Med Lett. 2008 Jan; 6(65):1-8
The drugs of choice for treatment of some fungal infections are listed in the tables. Some of the indications and dosages recommended here have not been approved by the FDA. Other guidelines are available from the Infectious Diseases Society of America ( www.idsociety.org ).
Issue 64 · December 1, 2007
Choice of Contraceptives

Transdermal, transvaginal and intrauterine hormone delivery systems have made highly effective contraceptive products more convenient to use. New oral contraceptive options include regimens with fewer or…

Treat Guidel Med Lett. 2007 Dec; 5(64):101-8
Transdermal, transvaginal and intrauterine hormone delivery systems have made highly effective contraceptive products more convenient to use. New oral contraceptive options include regimens with fewer or shorter hormone-free intervals.
Issue 57 · May 1, 2007
Choice of Antibacterial Drugs

Information about empirical treatment of bacterial infections, emerging trends in antimicrobial resistance, new drugs and new data about older drugs continue to become available. Usual pathogens and empiric…

Treat Guidel Med Lett. 2007 May; 5(57):33-50
Information about empirical treatment of bacterial infections, emerging trends in antimicrobial resistance, new drugs and new data about older drugs continue to become available. Usual pathogens and empiric treatment for some common types of infections are summarized in the text and a table listing the drugs of choice and alternatives for each pathogen begins on page 40. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants.
Issue 55 · March 1, 2007
Drugs for Tuberculosis

Even though the incidence continues to decline, tuberculosis (TB) is still a problem in the United States. Treatment of TB can be divided into treatment of latent infection and treatment of active disease.…

Treat Guidel Med Lett. 2007 Mar; 5(55):15-22
Even though the incidence continues to decline, tuberculosis (TB) is still a problem in the United States. Treatment of TB can be divided into treatment of latent infection and treatment of active disease. Atable listing the first-line drugs used for treatment of TB with their doses and adverse effects can be found on page 16. Other guidelines with more detailed management recommendations are available.
Issue 1228 · February 13, 2006
Treatment of Community-Associated MRSA Infections

Methicillin-resistant Staphylococcus aureus (MRSA) infections, which have been a concern for many years, previously occurred primarily in hospitalized patients and those recently treated with antibiotics. In…

Med Lett Drugs Ther. 2006 Feb 13; 48(1228):13-4
Methicillin-resistant Staphylococcus aureus (MRSA) infections, which have been a concern for many years, previously occurred primarily in hospitalized patients and those recently treated with antibiotics. In the past few years, there has been an increasing incidence worldwide of community-associated (CA) MRSA infections in patients without recent antibiotic exposure or contact with the healthcare system.
Issue 1221 · November 7, 2005
Ramelteon (Rozerem) for Insomnia

Ramelteon ( Rozerem - Takeda), a melatonin receptor agonist, has been approved by the FDA for treatment of insomnia characterized by difficulty falling asleep. Unlike all other prescription hypnotics, which…

Med Lett Drugs Ther. 2005 Nov 7; 47(1221):89-91
Ramelteon ( Rozerem - Takeda), a melatonin receptor agonist, has been approved by the FDA for treatment of insomnia characterized by difficulty falling asleep. Unlike all other prescription hypnotics, which are classified as schedule IV drugs, ramelteon is not a controlled substance.
Issue 1219 · October 10, 2005
Tipranavir (Aptivus) for HIV

Tipranavir ( Aptivus - Boehringer Ingelheim), a new protease inhibitor, has received accelerated approval from the FDA. It must be given with ritonavir ( Norvir ). The combination is indicated for use with…

Med Lett Drugs Ther. 2005 Oct 10; 47(1219):83-4
Tipranavir ( Aptivus - Boehringer Ingelheim), a new protease inhibitor, has received accelerated approval from the FDA. It must be given with ritonavir ( Norvir ). The combination is indicated for use with other antiretrovirals to treat HIV infection in highly treatment-experienced adults who have ongoing viral replication or in those with HIV strains known to be resistant to multiple protease inhibitors.
Issue 1215 · August 15, 2005
Sildenafil (Revatio) for Pulmonary Arterial Hypertension

The Medical Letter reported last year that sildenafil ( Viagra - Pfizer) appeared to be effective for idiopathic pulmonary arterial hypertension (PAH), but confirmation from a controlled trial was needed. Now…

Med Lett Drugs Ther. 2005 Aug 15; 47(1215):65-7
The Medical Letter reported last year that sildenafil ( Viagra - Pfizer) appeared to be effective for idiopathic pulmonary arterial hypertension (PAH), but confirmation from a controlled trial was needed. Now the results of such a study are about to be published, and the drug has been approved by the FDA for this indication under the trade name Revatio .
Issue 1212 · July 4, 2005
CYP3A and Drug Interactions

Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in…

Med Lett Drugs Ther. 2005 Jul 4; 47(1212):54-5
Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in the metabolism of more than 50 percent of currently prescribed drugs.2 CYP3A4, which is more abundantly expressed than CYP3A5, accounts for most CYP3A activity in vivo .
Issue 1205 · March 28, 2005
Erlotinib (Tarceva) for Advanced Non-Small Cell Lung Cancer

Erlotinib (Tarceva) is the second oral epidermal growth factor receptor (EGFR) inhibitor to become available in the US for treatment of advanced refractory NSCLC. In clinical trials, erlotinib produced a…

Med Lett Drugs Ther. 2005 Mar 28; 47(1205):25-6
Erlotinib (Tarceva) is the second oral epidermal growth factor receptor (EGFR) inhibitor to become available in the US for treatment of advanced refractory NSCLC. In clinical trials, erlotinib produced a response rate of only 8.9%, but increased median survival from 4.7 to 6.7 months. Patients who had never smoked and those with EGFR-positive tumors survived longer. Erlotinib is generally well tolerated; diarrhea and rash are the most common adverse effects.
Issue 1205 · March 28, 2005
Extended-Release Carbamazepine (Equetro) for Bipolar Disorder

An extended-release formulation of carbamazepine, available since 1997 for treatment of epilepsy, has now been approved under a new name, Equetro , for acute mania and mixed episodes of bipolar disorder.…

Med Lett Drugs Ther. 2005 Mar 28; 47(1205):27-8
An extended-release formulation of carbamazepine, available since 1997 for treatment of epilepsy, has now been approved under a new name, Equetro , for acute mania and mixed episodes of bipolar disorder. Although the drug was effective in some patients for up to 6 months, it has not been approved for maintenance treatment. Carbamazepine has not been shown to be more effective than lithium or valproate, and it can cause serious adverse effects.
Issue 30 · February 1, 2005
Antifungal Drugs

The drugs of choice for treatment of some fungal infections are listed in the table that begins on page 8. Some of the indications and dosages recommended here have not been approved by the FDA.

Treat Guidel Med Lett. 2005 Feb; 3(30):7-14
The drugs of choice for treatment of some fungal infections are listed in the table that begins on page 8. Some of the indications and dosages recommended here have not been approved by the FDA.
Issue 28 · December 1, 2004
Drugs for Tuberculosis

Tuberculosis (TB) is still a problem in the United States, even though the incidence continues to decline in most of the country (MMWR Morbid Mortal Wkly Rep 2004; 53:209). Treatment of TB can be divided into…

Treat Guidel Med Lett. 2004 Dec; 2(28):83-2
Tuberculosis (TB) is still a problem in the United States, even though the incidence continues to decline in most of the country (MMWR Morbid Mortal Wkly Rep 2004; 53:209). Treatment of TB can be divided into treatment of latent infection diagnosed by a positive PPD and treatment of active clinical TB. Guidelines with detailed management recommendations are available from the US Centers for Disease Control and Prevention (CDC) (MMWR Morbid Mortal Wkly Rep 2003; 52RR-11:1).
Issue 1189 · August 16, 2004
Telithromycin (Ketek) for Respiratory Infections

Telithromycin ( Ketek - Aventis) has been approved by the FDA for oral treatment of mild to moderate community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis in…

Med Lett Drugs Ther. 2004 Aug 16; 46(1189):66-8
Telithromycin ( Ketek - Aventis) has been approved by the FDA for oral treatment of mild to moderate community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis in patients age 18 and older. The drug is the first in a new class of antibiotics, the ketolides, derived from the macrolide erythromycin. Telithromycin has been marketed in Europe since 2001.
Issue 1189 · August 16, 2004
Drugs for Parasitic Infections

Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously…

Med Lett Drugs Ther. 2004 Aug 16; 46(1189):66
Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously unfamiliar parasites. The table below lists first-choice and alternative drugs for most parasitic infections. The brand names and manufacturers of the drugs are listed in this article.
Issue 24 · August 1, 2004
Choice of Contraceptives

In recent years, several new contraceptive options have become available in the United States. Novel hormone delivery systems such as transdermal, transvaginal and intrauterine devices have improved the…

Treat Guidel Med Lett. 2004 Aug; 2(24):55-62
In recent years, several new contraceptive options have become available in the United States. Novel hormone delivery systems such as transdermal, transvaginal and intrauterine devices have improved the convenience of highly effective contraceptive products. Like oral contraceptives and most barrier contraceptives, these devices do not protect against sexually transmitted diseases.
Issue 19 · March 1, 2004
Choice of Antibacterial Drugs

New drugs for bacterial infections and new information about older drugs continue to become available. Empirical treatment of some common bacterial infections is discussed in this article. A table listing the…

Treat Guidel Med Lett. 2004 Mar; 2(19):13-22
New drugs for bacterial infections and new information about older drugs continue to become available. Empirical treatment of some common bacterial infections is discussed in this article. A table listing the drugs of choice and alternatives for each pathogen begins on page 18. These recommendations are based on results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants. Local resistance patterns should be taken into account. Trade names are listed on page 24.
Issue 1175 · February 2, 2004
Daptomycin (Cubicin) for Skin and Soft Tissue Infections

Daptomycin ( Cubicin - Cubist), a cyclic lipopeptide (a new class of antibiotics), has been approved by the FDA for intravenous (IV) treatment of complicated skin and skin structure infections. It is being…

Med Lett Drugs Ther. 2004 Feb 2; 46(1175):11-2
Daptomycin ( Cubicin - Cubist), a cyclic lipopeptide (a new class of antibiotics), has been approved by the FDA for intravenous (IV) treatment of complicated skin and skin structure infections. It is being promoted as a once-daily bactericidal alternative to vancomycin ( Vancocin , and others) for methicillin-resistant Staphylococcus aureusinfections.
Issue 17 · January 1, 2004
Drugs for HIV

New drug approvals as well as continuing concerns about drug toxicity and the development of resistance have prompted new antiretroviral treatment guidelines (Panel on Clinical Practices for Treatment of HIV…

Treat Guidel Med Lett. 2004 Jan; 2(17):1-6
New drug approvals as well as continuing concerns about drug toxicity and the development of resistance have prompted new antiretroviral treatment guidelines (Panel on Clinical Practices for Treatment of HIV Infection, November 10, 2003, www.aidsinfo.nih.gov ).
Issue 1158 · June 8, 2003
Drug Interactions

Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug…

Med Lett Drugs Ther. 2003 Jun 8; 45(1158):46-8
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Issue 1127 · April 1, 2002
Drugs for Parasitic Infections

Superseded--purchase updated Parasitic Infections article Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS,…

Med Lett Drugs Ther. 2002 Apr 1; 44(1127):32
Superseded--purchase updated Parasitic Infections article Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously unfamiliar parasites. Note: Drugs for Parasitic Infections, revised and updated, is now available to both subscribers and nonsubscribers on our web site. This article, a bi-annual feature of The Medical Letter for many years, will not be published as a printed issue in 2002, but is included in the 16th edition of The Medical Letter Handbook of Antimicrobial Therapy. The handbook is now available and can be ordered by calling customer service at 1-800-211-2769.
Issue 1093 · November 27, 2000
Atovaquone/Proguanil (Malarone) for Malaria

A fixed-dose combination of atovaquone and proguanil hydrochloride has been approved by the FDA for oral prophylaxis and treatment of malaria due to Plasmodium falciparum , including choloroquine-resistant…

Med Lett Drugs Ther. 2000 Nov 27; 42(1093):109-11
A fixed-dose combination of atovaquone and proguanil hydrochloride has been approved by the FDA for oral prophylaxis and treatment of malaria due to Plasmodium falciparum , including choloroquine-resistant strains.
Issue 1091 · October 30, 2000
Mifepristone (RU 486)

Mifepristone (RU 486; Mifeprex - Danco), an antiprogestin, has been approved by the FDA for termination of intrauterine pregnancies of 49 days or less. It is generally used with misoprostol ( Cytotec -…

Med Lett Drugs Ther. 2000 Oct 30; 42(1091):101-2
Mifepristone (RU 486; Mifeprex - Danco), an antiprogestin, has been approved by the FDA for termination of intrauterine pregnancies of 49 days or less. It is generally used with misoprostol ( Cytotec - Searle), an E 1 prostaglandin analog marketed in the USA only for prevention of gastric ulcers.
Issue 1078 · May 15, 2000
Oral Contraceptives

Two types of oral contraceptives are available in the USA: combination oral contraceptives that contain both an estrogen and a progestin, and progestin-only contraceptives, or "mini-pills."Used as directed,…

Med Lett Drugs Ther. 2000 May 15; 42(1078):42-4
Two types of oral contraceptives are available in the USA: combination oral contraceptives that contain both an estrogen and a progestin, and progestin-only contraceptives, or "mini-pills."Used as directed, all oral contraceptives marketed in the USA are similarly effective in preventing pregnancy.
Issue 1071 · February 7, 2000
Sirolimus (Rapamune) for Transplant Rejection

Sirolimus, whlch is structurally related to tacrolimus, has been approved by the FDA for prevention of acute renal transplant rejection. The manufacturer recommends that sirolimus be taken with cyclosporine…

Med Lett Drugs Ther. 2000 Feb 7; 42(1071):13-4
Sirolimus, whlch is structurally related to tacrolimus, has been approved by the FDA for prevention of acute renal transplant rejection. The manufacturer recommends that sirolimus be taken with cyclosporine and corticosteroids.
Issue 1063 · October 8, 1999
Zaleplon for Insomnia

Zaleplon, a pyrazolopyrimidine hypnotic, was recently approved by the FDA for short-term treatment of insomia. Zaleplon, like zolpidem, is a non-benzodiazepine that binds to benzodiazepine receptors.

Med Lett Drugs Ther. 1999 Oct 8; 41(1063):93-4
Zaleplon, a pyrazolopyrimidine hypnotic, was recently approved by the FDA for short-term treatment of insomia. Zaleplon, like zolpidem, is a non-benzodiazepine that binds to benzodiazepine receptors.
Issue 1057 · July 16, 1999
Amprenavir: A New HIV Protease Inhibitor

Amprenavir is the fifth protease inhibitor to become available for treatment of HIV infection. It was approved by the FDA for use with other drugs in the treatment of HIV-infected adults and children at least…

Med Lett Drugs Ther. 1999 Jul 16; 41(1057):63-6
Amprenavir is the fifth protease inhibitor to become available for treatment of HIV infection. It was approved by the FDA for use with other drugs in the treatment of HIV-infected adults and children at least four years old.
Issue 1056 · July 2, 1999
Rofecoxib for Osteoarthritis and Pain

Rofecoxib, a selective COX-2 inhibitor, has been approved by the FDA for treatment of osteoarthritis, acute pain and menstrual pain.

Med Lett Drugs Ther. 1999 Jul 2; 41(1056):59-62
Rofecoxib, a selective COX-2 inhibitor, has been approved by the FDA for treatment of osteoarthritis, acute pain and menstrual pain.
Issue 1056 · July 2, 1999
Drug Interactions

Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new drugs.

Med Lett Drugs Ther. 1999 Jul 2; 41(1056):59-62
Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new drugs.
Issue 1047 · February 26, 1999
Rifapentine--A Long-Acting Rifamycin for Tuberculosis

Rifapentine, a long-acting analog of rifampin developed in the 1960's, has received an accelerated approval from the FDA for oral use, with at least one other drug, in the treatment of pulmonary tuberculosis.

Med Lett Drugs Ther. 1999 Feb 26; 41(1047):21-2
Rifapentine, a long-acting analog of rifampin developed in the 1960's, has received an accelerated approval from the FDA for oral use, with at least one other drug, in the treatment of pulmonary tuberculosis.
Issue 1046 · February 12, 1999
Drugs and Vaccines Against Biological Weapons

Concerns persist about the possible use of biological weapons. Among the many organisms found in nature that cause serious infections, only a few have the combination of pathogenicity, stability and ease of…

Med Lett Drugs Ther. 1999 Feb 12; 41(1046):15-6
Concerns persist about the possible use of biological weapons. Among the many organisms found in nature that cause serious infections, only a few have the combination of pathogenicity, stability and ease of production needed to make effective biological warefare agents.
Issue 1040 · November 20, 1998
New Drugs for Rheumatoid Arthritis

Leflunomide ( Arava - Hoechst Marion Roussel), which inhibits pyrimidine synthesis, and etanercept ( Enbrel - Immunex/Wyeth-Ayerst), which blocks the action of tumor necrosis factor (TNF), have been approved…

Med Lett Drugs Ther. 1998 Nov 20; 40(1040):110-2
Leflunomide ( Arava - Hoechst Marion Roussel), which inhibits pyrimidine synthesis, and etanercept ( Enbrel - Immunex/Wyeth-Ayerst), which blocks the action of tumor necrosis factor (TNF), have been approved by the FDA for treatment of rheumatoid arthritis. A third drug, infliximab ( Remicade - Centocor), which also blocks TNF and has been used to treat rheumatoid arthritis, was approved earlier for treatment of Crohn's disease. Its use in Crohn's disease will be reviewed in a future issue.
Issue 1017 · January 2, 1998
Drugs for Parasitic Infections

(Superseded by the 2013 version. Click here to purchase. ) Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS,…

Med Lett Drugs Ther. 1998 Jan 2; 40(1017):1-12
(Superseded by the 2013 version. Click here to purchase. ) Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously unfamiliar parasites. The table lists first-choice and alternative drugs for most parasitic infections.
Issue 1010 · September 26, 1997
Carvedilol for Heart Failure

Carvedilol ( Coreg - SmithKline Beecham and Boehringer-Mannheim), a betaadrenergic and alpha-adrenergic blocker approved by the FDA for treatment of hypertension in 1995, but not marketed at that time, has now…

Med Lett Drugs Ther. 1997 Sep 26; 39(1010):89-91
Carvedilol ( Coreg - SmithKline Beecham and Boehringer-Mannheim), a betaadrenergic and alpha-adrenergic blocker approved by the FDA for treatment of hypertension in 1995, but not marketed at that time, has now been approved and marketed for treatment of mild or moderate (NYHA class II or III) heart failure stabilized on other drugs. It is being promoted as an add-on drug that reduces the morbidity and mortality of the disease.
Issue 1009 · September 12, 1997
Systemic Antifungal Drugs

The drugs of choice for treatment of deep fungal infections are listed in the table below. Some of the indications and dosages recommended here have not been approved by the FDA.

Med Lett Drugs Ther. 1997 Sep 12; 39(1009):86-8
The drugs of choice for treatment of deep fungal infections are listed in the table below. Some of the indications and dosages recommended here have not been approved by the FDA.
Issue 972 · April 12, 1996
New Drugs for HIV Infection

The US Food and Drug Administration (FDA) has approved the marketing of five new drugs for treatment of HIV Infection. Stavudine (D4T; Zerit - Bristol-Myers Squibb) and lamivudine (3TC; Epivir - Glaxo…

Med Lett Drugs Ther. 1996 Apr 12; 38(972):35-7
The US Food and Drug Administration (FDA) has approved the marketing of five new drugs for treatment of HIV Infection. Stavudine (D4T; Zerit - Bristol-Myers Squibb) and lamivudine (3TC; Epivir - Glaxo Wellcome) are nucleoside analogs similar to zidovudine (AZT), didanosine (ddl) and zalcitabine (ddC). Saquinavir ( Invirase - Roche), ritonavir ( Norvir - Abbott) and indinavir ( Crixivan - Merck) are protease inhibitors, a new class of anti-HIV drugs.
Issue 967 · February 2, 1996
Systemic Antifungal Drugs

The drugs of choice for treatment of deep fungal infections are listed in the table on page 101. Some of the indications and dosages recommended here have not been approved by the US Food and Drug…

Med Lett Drugs Ther. 1996 Feb 2; 38(967):10-2
The drugs of choice for treatment of deep fungal infections are listed in the table on page 101. Some of the indications and dosages recommended here have not been approved by the US Food and Drug Administration. More detailed guidelines are available from the Infectious Diseases Society of America (J Sobel et al, Clin Infect Dis, volume 30, April 2000).
Issue 966 · January 19, 1996
Itraconazole for Onychomycosis

Itraconazole (Sporanox - Janssen), an oral antifungal triazole that has been available in the USA since 1992 for treatment of deep fungal infections (Medical Letter, 35:7, 1993), is now being marketed for…

Med Lett Drugs Ther. 1996 Jan 19; 38(966):5-6
Itraconazole (Sporanox - Janssen), an oral antifungal triazole that has been available in the USA since 1992 for treatment of deep fungal infections (Medical Letter, 35:7, 1993), is now being marketed for treatment of dermatophyte infections of the toenails, with or without fingernail involvement.
Issue 959 · October 13, 1995
Drugs for AIDS and Associated Infections

Results of recently completed clinical trials have led to some changes in recommendation for treatment of human immunodeficiency virus (HIV) and other infections associated with AIDS.

Med Lett Drugs Ther. 1995 Oct 13; 37(959):87-94
Results of recently completed clinical trials have led to some changes in recommendation for treatment of human immunodeficiency virus (HIV) and other infections associated with AIDS.
Issue 954 · August 4, 1995
Drugs For Tuberculosis

Tuberculosis (TB) continues to be a major problem in the United States, particularly in areas where drug resistance is common (Morbid Mortal Weekly Rep, 44:387, May 26, 1995). Since poor compliance is the most…

Med Lett Drugs Ther. 1995 Aug 4; 37(954):67-70
Tuberculosis (TB) continues to be a major problem in the United States, particularly in areas where drug resistance is common (Morbid Mortal Weekly Rep, 44:387, May 26, 1995). Since poor compliance is the most important cause of treatment failure and is associated with emergence of drug resistence, some experts now recommend that all patients take drugs for TB under direct observation (SE Weis et al, N Engl J Med, 330:1179, 1994; R Bayer and D Wilkinson, Lancet, 345:1545, June 17, 1995).
Issue 924 · June 10, 1994
LAAM - Long-Acting Methadone for Treatment of Heroin Addiction

Methadone, an opioid agonist that can be taken orally, has been used for maintenance treatment for many years in the USA (DM Novick et al, Drug Alcohol Depend, 33:235, 1993). Last year, the US Food and Drug…

Med Lett Drugs Ther. 1994 Jun 10; 36(924):52
Methadone, an opioid agonist that can be taken orally, has been used for maintenance treatment for many years in the USA (DM Novick et al, Drug Alcohol Depend, 33:235, 1993). Last year, the US Food and Drug Administration approved the distribution and use of L-alpha-acetyl-methadol (LAAM; ORLAAM - Bio Development Corporation, McLean, VA), a long-acting congener of methadone. LAAM, like methadone, will be available for this indication only through federal and state-regulated treatment programs.
Issue 923 · May 27, 1994
Fluvastatin for Lowering Cholesterol

Fluvastatin ( Lescol - Sandoz), an HMG-CoA reductase inhibitor, was recently marketed in the USA for treatment of hypercholesterolemia. A synthetic mevalonolactone derivative, it is chemically distinct from…

Med Lett Drugs Ther. 1994 May 27; 36(923):45-6
Fluvastatin ( Lescol - Sandoz), an HMG-CoA reductase inhibitor, was recently marketed in the USA for treatment of hypercholesterolemia. A synthetic mevalonolactone derivative, it is chemically distinct from previously available drugs in this class.
Issue 908 · October 29, 1993
Drugs for Tuberculosis

The rising incidence of tuberculosis (TB) has been accompanied by a dramatic increase in drug resistance in some areas of the USA (TR Frieden et al, N Engl J Med, 328:521, 1993). Since poor compliance is the…

Med Lett Drugs Ther. 1993 Oct 29; 35(908):99-102
The rising incidence of tuberculosis (TB) has been accompanied by a dramatic increase in drug resistance in some areas of the USA (TR Frieden et al, N Engl J Med, 328:521, 1993). Since poor compliance is the most important cause of treatment failure and associated with emergence of drug resistance, some experts now recommend that patients with TB take their drugs under direct obeservation (MD Iseman et al, N Engl J Med, 329:576, 1993).
Issue 904 · September 3, 1993
Drugs for AIDS and Associated infections

Results of recently completed clinical trials have led to some changes in recommendations for treatment of human immunodeficiency virus (HIV) and other infections associted with AIDS.

Med Lett Drugs Ther. 1993 Sep 3; 35(904):79-86
Results of recently completed clinical trials have led to some changes in recommendations for treatment of human immunodeficiency virus (HIV) and other infections associted with AIDS.
Issue 895 · April 30, 1993
Rifabutin

Rifabutin (formerly ansamycin; Mycobutin - Adria), a rifamycin antibiotic similar to rifampin (Rifadin, Rimactane) was recently approved by the US Food and Drug Administration for prevention of disseminated…

Med Lett Drugs Ther. 1993 Apr 30; 35(895):36-8
Rifabutin (formerly ansamycin; Mycobutin - Adria), a rifamycin antibiotic similar to rifampin (Rifadin, Rimactane) was recently approved by the US Food and Drug Administration for prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.
Issue 888 · January 22, 1993
Itraconazole

Itraconazole ( Sporanox - Janssen), an antifungal triazole, has been approved by the US Food and Drug Administration (FDA) for oral treatment of histoplasmosis and blastomycosis. These two endemic mycoses…

Med Lett Drugs Ther. 1993 Jan 22; 35(888):7-9
Itraconazole ( Sporanox - Janssen), an antifungal triazole, has been approved by the US Food and Drug Administration (FDA) for oral treatment of histoplasmosis and blastomycosis. These two endemic mycoses occur both in normal hosts and in immunocompromised patients, such as those with AIDS (RW Bradsher, Clin Infect Dis, 14:S82, 1992; LJ Wheat, Clin Infect Dis, 14:S91, 1992).
Issue 863 · February 7, 1992
Drugs for Tuberculosis

After many years of decline in the USA, the incidence of tuberculosis (TB) has recently increased, partly because the disease occurs more frequently in patients with human immunodeficiency virus (HIV)…

Med Lett Drugs Ther. 1992 Feb 7; 34(863):10-2
After many years of decline in the USA, the incidence of tuberculosis (TB) has recently increased, partly because the disease occurs more frequently in patients with human immunodeficiency virus (HIV) infection and in the homeless (PF Barnes et al, N Engl J Med, 324:1644, 1991; Morbid Mortal Weekly Rep, 40:869, Dec 20, 1991).
Issue 820 · June 15, 1990
Drugs for Treatment of Fungal Infections
Med Lett Drugs Ther. 1990 Jun 15; 32(820):58-60
Issue 818 · May 18, 1990
Fluconazole

Fluconazole ( Diflucan - Roerig), an antifungal azole, was recently approved by the US Food and Drug Administration for oral and intravenous (IV) treatment of cryptococcal meningitis and various forms of…

Med Lett Drugs Ther. 1990 May 18; 32(818):50-2
Fluconazole ( Diflucan - Roerig), an antifungal azole, was recently approved by the US Food and Drug Administration for oral and intravenous (IV) treatment of cryptococcal meningitis and various forms of candidiasis. Both cryptococcal meningitis and candidiasis occur frequently in patients with AIDS, organ transplants, or cancer.
Issue 763 · April 8, 1988
Drugs for Tuberculosis

After many years of decline, the incidence of tuberculosis has recently increased because the disease occurs in patients with AIDS (Morbid Mortal Weekly Rep, 36:817, Jan 1, 1988). For uncomplicated…

Med Lett Drugs Ther. 1988 Apr 8; 30(763):43-4
After many years of decline, the incidence of tuberculosis has recently increased because the disease occurs in patients with AIDS (Morbid Mortal Weekly Rep, 36:817, Jan 1, 1988). For uncomplicated tuberculosis, the recent trend in tuberculosis treatment has been toward a shorter period of therapy and increased use of pyrazinamide.
Issue 761 · March 11, 1988
Drugs For Treatment of Deep Fungal Infections

The incidence of opportunistic deep fungal infections continues to increase, particularly among patients who have AIDS, are taking immunosuppressive drugs, or are in intensive care units.

Med Lett Drugs Ther. 1988 Mar 11; 30(761):30-2
The incidence of opportunistic deep fungal infections continues to increase, particularly among patients who have AIDS, are taking immunosuppressive drugs, or are in intensive care units.